Fig 1: In vitro validation of the SMC DDC assay. Limits of quantification (a), parallelism (b), spike-in recovery (c), and dilution linearity (d). Mean ± SD of technical duplicates are plotted. Vertical dashed lines represent LLOQ and ULOQ. Horizontal dashes lines represent the +/- 30% validation criterium.
Fig 2: CSF DDC levels of dopaminergic drug-naïve patients with PD and SWEDD and Ctrl. a. Comparison of CSF DDC levels among the groups. For each individual, the mean value of technical duplicates is plotted. Horizontal bars correspond to median ± 95% CI. All CSF Ctrl and PD samples are SAA- and SAA+, respectively. CSF SAA+ SWEDD are highlighted in red. P-values are from multiple linear regression analysis of log2 CSF DDC data, including sex and age as covariates. b. Receiver operating characteristic analysis. ROC analysis was not corrected for age and sex difference.
Fig 3: Prognostic potential of CSF DDC levels in dopaminergic drug-naïve PD patients. a. MDS-UPDRS total score OFF changes over time in PD patients with low and high baseline CSF DDC levels after splitting at the median. b. Spearman correlation of baseline CSF DDC levels with MDS-UPDRS total score OFF changes for years 1–8.
Fig 4: Correlation of CSF DDC levels with DaT-SPECT SBRs from the contralateral caudate (a) and putamen (b).
Supplier Page from R&D Systems, a Bio-Techne Brand for Dopa Decarboxylase/DDC Protein
Available conjugates: Sizes Available: 10 ug